Synopsis of recent research by authors named "Merle Diamond"
Merle Diamond's recent research primarily focuses on the prevention and treatment of chronic and episodic migraine using various pharmacological approaches, including atogepant and eptinezumab, both of which target the calcitonin gene-related peptide (CGRP) receptor.
The findings highlight the efficacy, safety, and tolerability of these treatments, suggesting that combination therapy with atogepant and onabotulinumtoxinA may enhance outcomes for chronic migraine patients.
Additionally, the research emphasizes the potential for eptinezumab to significantly reduce headache frequency and the reliance on acute medications in patients with chronic migraine and medication-overuse headache.